CM Life Sciences III

EQRx, Inc. is a pharmaceutical company, which engages in developing and delivering innovative medicines to patients having chronic conditions. The company was founded by Alexis A. Borisy, Sandra J. Horning, Robert M. Forrester, Peter Bach, and Melanie I. Nallicheri on August 26, 2019 and is headquartered in Cambridge, MA.

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q3 2024

EQRx resets strategy to focus on high-value medicines and savings

EQRx is strategically focusing on high-value medicines and optimizing its portfolio for long-term growth and profitability.
Despite workforce reductions and strategic shifts, the company maintains a strong capital position and promising clinical data for Lerociclib.
Challenges lie in workforce reductions and revenue disruptions from terminating agreements, but opportunities exist in strategic acquisitions and new partnerships.
By balancing cost-cutting measures with growth initiatives, EQRx aims to enhance operational efficiency and drive future success.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

NEW YORK , Oct. 26, 2023 /PRNewswire/ -- Attorney Advertising--Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of CM Life Sciences III Inc.  ("CM Life Sciences"), which was acquired by EQRx, Inc. ("EQRx") (NASDAQ: EQRX) on August 5, 2021. Investors who purchased CM Life Sciences and continue to hold EQRx to the present, are encouraged to obtain additional information and assist the investigation by visiting the firm's site: bgandg.com/eqrx.

Calling All EQRx, Inc. (EQRX) Investors: Contact Bronstein, Gewirtz & Grossman, LLC To Claim Your Losses

bluebird bio

Virgin Galactic

Are you looking for the best penny stocks to buy now? Today might be your day

Best Penny Stocks To Buy Now? These 3 Are Moving Fast In October

Revolution Medicines

NEW ORLEANS--(BUSINESS WIRE)--Former Attorney General of Louisiana Charles C. Foti, Jr., Esq. and the law firm of Kahn Swick & Foti, LLC (“KSF”) are investigating the proposed sale of EQRx, Inc. (NasdaqGM: EQRX) to Revolution Medicines, Inc. (NasdaqGS: RVMD). Under the terms of the proposed transaction, shareholders of EQRx will receive the number of shares of Revolution Medicines common stock equal to the sum of 7,692,308 Revolution Medicines shares (determined as $200 million divided by $.

EQRX INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of EQRx, Inc. - EQRX

SAN DIEGO--(BUSINESS WIRE)---- $EQRX #CMLifeSciencesIIIInc--EQRx, Inc. (EQRX) May Have Engaged in a Conflicted SPAC Process.

EQRX Shareholder Investigation: Robbins LLP Reminds Shareholders it is Investigating EQRx, Inc. on behalf of Shareholders

EQRx (EQRX) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.

Should You Buy EQRx (EQRX) Ahead of Earnings?

MILWAUKEE , Aug. 2, 2023 /PRNewswire/ -- Ademi LLP is investigating EQRx (Nasdaq: EQRX) for possible breaches of fiduciary duty and other violations of law in its transaction with Revolution Medicines.  Click here to learn how to join the action https://www.ademilaw.com/case/eqrx-inc or call Guri Ademi toll-free at 866-264-3995.

Shareholder Alert: Ademi LLP investigates whether EQRx, Inc. has obtained a Fair Price in its transaction with Revolution Medicines

Ardelyx

Rite Aid

Penny stocks are an interesting asset class. On any given day, you will see at least a handful experiencing extreme levels and explosive moves.

Best Penny Stocks To Watch After Fitch Downgrade? 3 For Your List

NEW YORK--(BUSINESS WIRE)--Halper Sadeh LLC, an investor rights law firm, is investigating whether the merger of EQRx, Inc. (NASDAQ: EQRX) and Revolution Medicines, Inc. is fair to EQRx shareholders. Halper Sadeh encourages EQRx shareholders to click here to learn more about their legal rights and options or contact Daniel Sadeh or Zachary Halper at (212) 763-0060 or sadeh@halpersadeh.com or zhalper@halpersadeh.com. The investigation concerns whether EQRx and its board violated the federal secu.

EQRX Stock Alert: Halper Sadeh LLC Is Investigating Whether the Merger of EQRx, Inc. Is Fair to Shareholders

Revolution Medicines Inc. RVMD, +2.10% said Tuesday it has reached a definitive agreement to acquire EQRx Inc. EQRX, in an all-cash deal that's expected to add more than $1 billion in net cash to its balance sheet. Revolution Medicines specializes in therapies for RAS-addicted cancers, or those that are caused by mutations in RAS genes.

Revolutin Medicines to acquire EQRx in deal that will add $1 billion in cash to its balance sheet to fund R&D

Call Start: 16:30 January 1, 0000 4:57 PM ET EQRx, Inc. (NASDAQ:EQRX ) Q1 2023 Earnings Conference Call May 8, 2023 16:30 ET Company Participants Michelle Greenblatt - Head of Investor Relations Melanie Nallicheri - President & Chief Executive Officer Eric Hedrick - Chief Physician Executive Conference Call Participants Chris Shibutani - Goldman Sachs Chris Schott - JPMorgan Stephen Scala - TD Cowen Operator Good afternoon and welcome to the EQRx First Quarter 2023 Financial Results Conference Call. [Operator Instructions] Please be advised that this conference call is being recorded.

EQRx, Inc. (EQRX) Q1 2023 Earnings Call Transcript

CAMBRIDGE, Mass., May 08, 2023 (GLOBE NEWSWIRE) -- EQRx, Inc. (Nasdaq: EQRX), today announced plans to reset its business and reported financial results for the first quarter ended March 31, 2023.

EQRx Resets to Focus on Clinically Differentiated Medicines, Leveraging $1.3 Billion Cash Position; Reports First Quarter 2023 Financial Results

CAMBRIDGE, Mass., April 27, 2023 (GLOBE NEWSWIRE) -- EQRx, Inc. (Nasdaq: EQRX), a new type of pharmaceutical company committed to developing and expanding access to innovative medicines for some of the most prevalent disease areas, including cancer and immune-inflammatory conditions, today announced it will host a conference call and webcast on Monday, May 8, 2023, at 4:30 p.m. ET to report its first quarter 2023 financial results and provide a business update.

EQRx to Hold First Quarter 2023 Financial Results Conference Call on Monday, May 8, 2023

SAN DIEGO--(BUSINESS WIRE)---- $EQRX #CMLifeScciencesIII--EQRx, Inc.

EQRx, Inc. (EQRX) Shareholder Investigation: Robbins LLP is Investigating EQRX, Inc. on behalf of Shareholders

EQRx, Inc. (EQRX) is technically in oversold territory now, so the heavy selling pressure might have exhausted. This along with strong agreement among Wall Street analysts in raising earnings estimates could lead to a trend reversal for the stock.

After Plunging -17.33% in 4 Weeks, Here's Why the Trend Might Reverse for EQRx, Inc. (EQRX)

EQRx Reports Fourth Quarter and Full Year 2022 Financial Results and Recent Corporate Progress

After losing some value lately, a hammer chart pattern has been formed for EQRx, Inc. (EQRX), indicating that the stock has found support. This, combined with an upward trend in earnings estimate revisions, could lead to a trend reversal for the stock in the near term.

EQRx, Inc. (EQRX) May Find a Bottom Soon, Here's Why You Should Buy the Stock Now

CAMBRIDGE, Mass., Jan. 03, 2023 (GLOBE NEWSWIRE) -- EQRx, Inc. (Nasdaq: EQRX), a new type of pharmaceutical company committed to developing and expanding access to innovative medicines for some of the most prevalent disease areas, including cancer and immune-inflammatory conditions, today announced that management will present at the 41st Annual J.P. Morgan Healthcare Conference on Wednesday, January 11, 2023, at 4:30 p.m. PST / 7:30 p.m. EST.

EQRx to Present at the 41st Annual J.P. Morgan Healthcare Conference

CAMBRIDGE, Mass., Dec. 19, 2022 (GLOBE NEWSWIRE) -- EQRx, Inc. (Nasdaq: EQRX), a new type of pharmaceutical company committed to developing and expanding access to innovative medicines for some of the most prevalent disease areas, including cancer and immune-inflammatory conditions, today announced that the United Kingdom's (U.K.) Medicines and Healthcare products Regulatory Agency (MHRA) has accepted for review its marketing authorization application (MAA) for sugemalimab, an anti-programmed death-ligand 1 (PD-L1) antibody, in combination with chemotherapy for the first-line treatment of adult patients with metastatic non-small cell lung cancer (NSCLC).

EQRx Announces Acceptance of Marketing Authorization Application by the UK's Medicines and Healthcare Products Regulatory Agency for Sugemalimab in Metastatic Non-small Cell Lung Cancer

The heavy selling pressure might have exhausted for EQRx, Inc. (EQRX) as it is technically in oversold territory now. In addition to this technical measure, strong agreement among Wall Street analysts in revising earnings estimates higher indicates that the stock is ripe for a trend reversal.

Here's Why EQRx, Inc. (EQRX) is Poised for a Turnaround After Losing 23% in 4 Weeks

CAMBRIDGE, Mass., Dec. 02, 2022 (GLOBE NEWSWIRE) -- EQRx, Inc. (Nasdaq: EQRX), a new type of pharmaceutical company committed to developing and expanding access to innovative medicines for some of the most prevalent disease areas, including cancer and immune-inflammatory conditions, today announced that the European Medicines Agency (EMA) has accepted for review its marketing authorization application (MAA) for aumolertinib, a third-generation epidermal growth factor receptor (EGFR)-tyrosine kinase inhibitor (TKI) in development for the first-line treatment of adult patients with locally advanced or metastatic non-small cell lung cancer (NSCLC) with activating EGFR mutations, and for adult patients with locally advanced or metastatic EGFR T790M mutation-positive NSCLC.

EQRx Announces Acceptance of Marketing Authorization Application by the European Medicines Agency for Aumolertinib in EGFR-Mutated Non-small Cell Lung Cancer

EQRx, Inc. (NASDAQ:EQRX ) Q3 2022 Earnings Conference Call November 10, 2022 8:00 AM ET Company Participants Neil Swami - Head, Investor Relations Melanie Nallicheri - President and Chief Executive Officer Jami Rubin - Chief Financial Officer Eric Hedrick - Chief Physician Executive Conference Call Participants Steve Scala - Cowen Chris Schott - JPMorgan Operator Good morning and welcome to the EQRx Third Quarter 2022 Financial Results Conference Call. [Operator Instructions] Please be advised that this conference call is being recorded.

EQRx, Inc. (EQRX) Q3 2022 Earnings Call Transcript

Share of EQRx plunged 28.6% after the drugmaker said it would sell two cancer drugs at market prices, instead of the cut-rate prices it had promised.

A Biotech Steps Back From Bold Plan to Drop Drug Prices. A Stunning Selloff.

The company suspended trials for one of its lead therapies.

Why EQRx Shares Dropped 28.62% on Thursday

Why Earnings Season Could Be Great for EQRx (EQRX)

CAMBRIDGE, Mass., Nov. 07, 2022 (GLOBE NEWSWIRE) -- EQRx, Inc. (Nasdaq: EQRX), a new type of pharmaceutical company committed to developing and delivering innovative medicines to patients at substantially lower prices, today announced that management will participate in a fireside chat at the Jefferies 2022 London Healthcare Conference on Thursday, November 17, 2022, at 1:30 p.m. GMT / 8:30 a.m. EST.

News for CM Life Sciences III Stock (EQRX)